OMedLive

CME Speakers

 

  • Russell R. Broaddus, MD, PhD

    Russell R. Broaddus, MD, PhD

    Russell R. Broaddus, MD, PhD

    Professor, Department of Pathology

    Russell R. Broaddus, MD, is a professor with tenure in the Department of Pathology, Division of Pathology/Lab Medicine, at the University of Texas MD Anderson Cancer Center in Houston. He is one of two principal investigators for the NCI-funded Endometrial Cancer Sponsored Program of Research Excellence (SPORE) at MD Anderson. Currently, his research focuses on endometrial cancer, specifically, molecular mechanisms of pathogenesis, molecular diagnostics and clinical pathology laboratory assays for the identification of women with Lynch Syndrome. Dr. Broadus has authored more than 220 manuscripts in peer-reviewed journals, and is a two-time recipient of the John P. McGovern Outstanding Teacher Award from the MD Anderson Cancer Center/UT Health Graduate School of Biomedical Sciences.
  • Michael J. Overman, MD

    Michael J. Overman, MD

    Michael J. Overman, MD

    Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine

    Michael J. Overman, MD, is an associate professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston. Dr Overman is focused on improving the outcomes for patients with pancreatic and intestinal cancers, with a strong interest in clinical trials and translational research. He is a principal investigator on numerous studies investigating immune-checkpoint therapy in gastrointestinal malignancies, and has been involved in various clinical trial studies involving small bowel adenocarcinomas. He has published articles in peer-reviewed journals that include the Journal of Clinical Oncology and Annals of Oncology. Dr Overman earned his MD from Johns Hopkins School of Medicine in Baltimore, Maryland.
  • Jennifer Saggio, MSN, CRNP, CPON

    Jennifer Saggio, MSN, CRNP, CPON

    Jennifer Saggio, MSN, CRNP, CPON

    Neuroblastoma Nurse Practitoner

    Jennifer Saggio, RN, MSN, CRNP, CPON, MSN, is a neuroblastoma nurse practitioner at The Children’s Hospital of Philadelphia (CHOP) in Pennsylvania, and has been a nurse practitioner in the Division of Oncology at CHOP for the past 18 years. Ms Saggio coordinates care for children with recurrent/refractory neuroblastoma, and provides consultations to physicians, nurses, and families in order to meet the complex needs of both hospitalized and ambulatory patients with neuroblastoma. Her team cares for patients who live in the Philadelphia region, those who travel from throughout the United States, and to a large population of international patients as well. She received her graduate degree from the Pediatric Acute/Chronic Care NP Program at the University of Pennsylvania in Philadelphia.
  • Erin Armideo, CRNP, RN, CPON

    Erin Armideo, CRNP, RN, CPON

    Erin Armideo, CRNP, RN, CPON

    Pediatric Oncology Nurse Pracitioner

    Erin Armideo, RN, MSN, CRNP, CPON, is a nurse practitioner at The Children’s Hospital of Philadelphia (CHOP) in Pennsylvania, where she began her career as a pediatric oncology nurse. She earned her bachelors of nursing from the Pennsylvania State University and a master’s degree in nursing from the University of Pennsylvania, Pediatric Acute Care Nurse Practitioner program. Ms Armideo has cared for patients with various types of solid tumors in both inpatient and outpatient settings. Her passion is educating patients and families about their child’s disease, treatment and side effects of treatment. She has presented in various forums, including internationally on the management of side effects related to immunotherapy, and has received awards from CHOP and the Philadelphia City Council.
  • Gregory C. Hedler, MSW, LCSW

    Gregory C. Hedler, MSW, LCSW

    Gregory C. Hedler, MSW, LCSW

    Social Worker, Cancer Center

    Gregory C. Hedler, MSW, LCSW, is a licensed clinical social worker at the Children’s Hospital of Philadelphia (CHOP) in Pennsylvania. Focusing his supportive efforts on newly diagnosed high-risk neuroblastoma, as well as relapsed or refractory neuroblastoma, he offers 13 years of experience in pediatric oncology to these patients and their families, tailoring his therapeutic interventions to meet the nuanced psychosocial needs associated with recurrent and refractory disease. Before joining CHOP, he worked at The Children's Cancer Institute at Hackensack University Medical Center in New Jersey, caring for patients with various types of childhood cancers as well as those with sickle cell disease. Mr Hedler received his master of social work from Fordham University in New York, New York.
  • Daniel J. George, MD

    Daniel J. George, MD

    Daniel J. George, MD

    Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology

    Daniel J. George, MD, is a professor of medicine and surgery in the Divisions of Medical Oncology and Urology at Duke University School of Medicine in Durham, North Carolina. He also has appointments in the Duke Clinical Research Institute and the Duke Cancer Institute, where he is the director of genitourinary (GU) oncology. Dr George’s areas of research include new drug development and biomarkers of GU cancers with an emphasis on signal transduction pathways and angiogenesis. He leads the Duke site for the Department of Defense Prostate Cancer Clinical Trials Consortium, specializing in Phase I and II studies in prostate cancer. Dr George is an internationally recognized clinical researcher and thought leader in GU malignancies, with over 150 peer-reviewed publications.
  • Neal D. Shore, MD, FACS

    Neal D. Shore, MD, FACS

    Neal D. Shore, MD, FACS

    President

    Neal D. Shore, MD, FACS, is the medical director for the Carolina Urologic Research Center and practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr Shore has conducted more than 250 clinical trials that focus mainly on GU oncology, serves on the executive boards of the Society of Urologic Oncology, Bladder Cancer Advocacy Network and the Society of Urologic Oncology Clinical Trials Consortium, and is president of the Large Urology Group Practice Association. He is a founder for the CUSP Clinical Trials Consortium and DASHKO, large urology practices data registries. He has over 125 peer-reviewed publications, several book chapters, and is a peer reviewer for Lancet Oncology, Urology, and numerous other journals. He earned his MD from Duke University Medical School.
  • Jonathan W. Friedberg, MD, MMSc

    Jonathan W. Friedberg, MD, MMSc

    Jonathan W. Friedberg, MD, MMSc

    University of Rochester

  • John P. Leonard, MD

    John P. Leonard, MD